CKD: FDA approves expanded indication for ferric citrate

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The FDA has approved an expanded indication for ferric citrate tablets (Auryxia), allowing their use for the treatment of iron deficiency anemia in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD).

Why this matters

  • Use of the phosphate binder was previously limited to patients on dialysis.
  • For patients not on dialysis, the starting dose is 1 tablet (rather than 2), three times daily.

Study design

  • Approval was based on phase 3 data from a 16-wk randomized, double-blind, placebo-controlled efficacy trial, followed by an 8-wk open-label safety extension study, in 232 adults (mean age, 65 y; female, 63%)  with stage III-V NDD-CKD.
  • Hb levels ranged from 9.0-11.5 g/dL.
  • Funding: Keryx Biopharmaceuticals, Inc.

Key results

  • Ferric citrate was significantly more effective than placebo for achieving an increase in Hb ≥1.0 g/dL at any point over the 16-wk period (52.1% vs 19.1%; P<.001>
  • Proportion of patients achieving a sustained increase in Hb (≥0.75 g/dL during any 4-wk period) was likewise higher (49% vs 15%; P<.001>
  • Mean change in Hb from baseline was 0.75±0.09 g/dL.
  • Most common adverse events were diarrhea (21%), constipation (19%), discolored feces (15%), nausea (11%), abdominal pain (6%), and hyperkalemia (7%).

For Prescribing Information, click here.